Tuesday, September 23, 2025

Pfizer Strengthens Obesity Portfolio with Acquisition of Metsera

Pfizer Inc. (NYSE: PFE) has announced the acquisition of Metsera, Inc. (NASDAQ: MTSR), a clinical-stage biopharmaceutical company developing novel therapies for obesity and cardiometabolic diseases. The transaction, valued at $4.9 billion, was unanimously approved by both companies’ Boards of Directors. In addition, Metsera shareholders may receive up to an extra $22.50 per share through a Contingent Value Right (CVR) tied to key clinical and regulatory milestones.

With this move, Pfizer aims to significantly strengthen its position in a rapidly growing market. Obesity is associated with more than 200 health conditions. Pfizer CEO Albert Bourla emphasized that the acquisition aligns perfectly with the company’s strategy: “This transaction accelerates our entry into a major therapeutic area and creates the opportunity to reach millions of patients worldwide with innovative treatments.”

Metsera’s portfolio includes four clinical-stage programs and several additional candidates in preparation, such as:

• MET-097i, a GLP-1 receptor agonist for weekly and monthly injections (Phase 2),
• MET-233i, a monthly amylin analog candidate (Phase 1), also in combination with MET-097i,
• two oral GLP-1 candidates expected to enter clinical trials soon.

The acquisition highlights Pfizer’s ambition to deliver best-in-class solutions in obesity and metabolic therapies. The transaction is expected to close in Q4 2025, subject to regulatory approvals and approval by Metsera shareholders.

Metsera CEO Whit Bernard described the deal as “an excellent outcome for shareholders and a decisive step toward improving the lives of hundreds of millions of people worldwide.”

Pfizer will provide further updates on financial impacts during its upcoming quarterly earnings.